References
- Baribault H, Majeti JZ, Ge H, et al. Advancing therapeutic discovery through phenotypic screening of the extracellular proteome using hydrodynamic intravascular injection. Expert Opin Ther Targets. 2014;18:1253–1264.
- Bennett J, Wellman J, Marshall KA, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016;388:661–672.
- Geisler A, Fechner H. MicroRNA-regulated viral vectors for gene therapy. World J Exp Med. 2016;6:37–54.
- Lee KJ, Plewa C, Sheng J, et al. High titer recombinant AAV vector production in adherent and suspension cells. WO. 2015;2015031686:A2015031681.
- Srivastava A. In vivo tissue-tropism of adeno-associated viral vectors. Curr Opin Virol. 2016;21:75–80.
- Zhao H, Wolfe T, Plewa C, et al. Scalable single-step affinity purification of rAAV vector using AVB-sepharose yields high purity and high titer vector. Mol Ther. 2012;20:S230.
- Ge H, Zhang J, Gong Y, et al. Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions. J Biol Chem. 2014;289:30470–30480.